Business
Half-year Financial Report
Tristel plc reported a strong first half for the period ending December 31, 2025, with revenue increasing by 14% to £25.65 million, driven by a 13% rise in UK sales to £9.88 million and a 14% increase in overseas sales to £15.77 million, notably a sixfold growth in the USA. Adjusted EBITDA rose by 17% to £7.34 million, and reported profit before tax increased by 36% to £4.96 million. The company remains debt-free with cash and short-term investments totaling £13.29 million and maintained its interim dividend at 5.68 pence per share. Significant operational developments include the US launch of Tristel OPH and updated AIUM guidelines supporting chlorine dioxide for HLD of ultrasound probes. Disclaimer*
About this update from Tristel Plc
2 March 2026 TRISTEL plc ("Tristel", the "Company" or the "Group") Half-year Report Unaudited Interim Results for the six months ended 31 December 2025 Tristel plc (AIM: TSTL), the manufacturer of infection prevention products utilising proprietary chlorine dioxide technology, announces its unaudited interim results for the six months to 31 December 2025, a period which delivered revenue growth and a 17% increase in adjusted EBITDA. The Company remains cash generative, with no debt, and maintains a progressive dividend policy with a consistent interim payment. Financial highlights · Revenue up 14% to £25.65m (2024: £22.57m) with the business firmly on track to meet market expectations for the year · UK sales up 13% to £9.88m (2024: £8.75m); Overseas sales up 14% to £15.77m (2024: £13.82m) with a sixfold growth in the USA · Gross margin remains steady at 81% (2024: 82%) · Reported EBITDA up to £6.83m (2024: £5.02m) o Adjusted* EBITDA up 17% to £7.34m (2024: £6.27m) · Reported profit before tax up 36% to £4.96m (2024: £3.66m) o Adjusted* profit before tax up 11% to £5.47m (2024: £4.91m) · Basic reported EPS 8.28p (2024: 5.72p) up 45%. o Basic adjusted* EPS 9.36p (2024: 8.17p) · Tax charge £1.00m (2024: £0.93m) · Interim dividend unchanged at 5.68p per share (2024: 5.68p) · No debt and cash and short-term investments of £13.29m (2024: £11.74m) after paying dividends of £4.07m (2024: £3.94m). *Adjusted for share-based payments (£0.39m) and exceptional succession costs (£0.13m), totalling £0.52m (2024: £1.25m) Operational highlights · Appointment of Anna Wasyl as CFO · Launch of Tristel OPH in the US, a high-level disinfectant (HLD) foam for use on ophthalmic medical devices · Updated American Institute of Ultrasound in Medicine (AIUM) guidelines now include chlorine dioxide for HLD of ultrasound probes, strengthening the clinical and commercial adoption framework for Tristel ULT™ in the US market · Launch of VISICLEAN™, expa...